Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertraline

Detalhes bibliográficos
Autor(a) principal: Rahman, Mohammad Akhlaquer
Data de Publicação: 2018
Outros Autores: Mujahid, Mohammad
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Pharmaceutical Sciences
Texto Completo: https://www.revistas.usp.br/bjps/article/view/146836
Resumo: The purpose of the study was to combine the advantages of self-nanoemulsifying drug delivery systems and tablets as a conventional dosage form. Self-nanoemulsifying drug delivery system (SNEDDS) was prepared to enhance the solubility and thus oral bioavailability of sertraline. Aqueous titration method was used to prepare the liquid SNEDDS; ternary phase diagrams were constructed and based on smaller droplet size (24.8 nm), minimum viscosity (153.63 cP) and polydispersity index (0.182), higher percentage transmittance (95%) and in vitro drug release (97%), an optimum system was designated. Liquid SNEDDS was transformed into free-flowing powder by solid adsorption technique followed by compression into tablets. In vitro release of sertraline from liquid and solid SNEDDS was found to be highly significant compared to plain sertraline (p
id USP-31_ca38e3b857daaebf31edb3957ffa65de
oai_identifier_str oai:revistas.usp.br:article/146836
network_acronym_str USP-31
network_name_str Brazilian Journal of Pharmaceutical Sciences
repository_id_str
spelling Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertralineSNEDDSPhase diagramsSolubilityThermodynamic stabilityOral deliveryBioavailability The purpose of the study was to combine the advantages of self-nanoemulsifying drug delivery systems and tablets as a conventional dosage form. Self-nanoemulsifying drug delivery system (SNEDDS) was prepared to enhance the solubility and thus oral bioavailability of sertraline. Aqueous titration method was used to prepare the liquid SNEDDS; ternary phase diagrams were constructed and based on smaller droplet size (24.8 nm), minimum viscosity (153.63 cP) and polydispersity index (0.182), higher percentage transmittance (95%) and in vitro drug release (97%), an optimum system was designated. Liquid SNEDDS was transformed into free-flowing powder by solid adsorption technique followed by compression into tablets. In vitro release of sertraline from liquid and solid SNEDDS was found to be highly significant compared to plain sertraline (pUniversidade de São Paulo. Faculdade de Ciências Farmacêuticas2018-06-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/14683610.1590/s2175-97902018000117232Brazilian Journal of Pharmaceutical Sciences; Vol. 54 Núm. 1 (2018); e17232Brazilian Journal of Pharmaceutical Sciences; v. 54 n. 1 (2018); e17232Brazilian Journal of Pharmaceutical Sciences; Vol. 54 No. 1 (2018); e172322175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/146836/140365Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)info:eu-repo/semantics/openAccessRahman, Mohammad AkhlaquerMujahid, Mohammad2018-06-07T16:31:56Zoai:revistas.usp.br:article/146836Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2018-06-07T16:31:56Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertraline
title Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertraline
spellingShingle Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertraline
Rahman, Mohammad Akhlaquer
SNEDDS
Phase diagrams
Solubility
Thermodynamic stability
Oral delivery
Bioavailability
title_short Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertraline
title_full Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertraline
title_fullStr Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertraline
title_full_unstemmed Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertraline
title_sort Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertraline
author Rahman, Mohammad Akhlaquer
author_facet Rahman, Mohammad Akhlaquer
Mujahid, Mohammad
author_role author
author2 Mujahid, Mohammad
author2_role author
dc.contributor.author.fl_str_mv Rahman, Mohammad Akhlaquer
Mujahid, Mohammad
dc.subject.por.fl_str_mv SNEDDS
Phase diagrams
Solubility
Thermodynamic stability
Oral delivery
Bioavailability
topic SNEDDS
Phase diagrams
Solubility
Thermodynamic stability
Oral delivery
Bioavailability
description The purpose of the study was to combine the advantages of self-nanoemulsifying drug delivery systems and tablets as a conventional dosage form. Self-nanoemulsifying drug delivery system (SNEDDS) was prepared to enhance the solubility and thus oral bioavailability of sertraline. Aqueous titration method was used to prepare the liquid SNEDDS; ternary phase diagrams were constructed and based on smaller droplet size (24.8 nm), minimum viscosity (153.63 cP) and polydispersity index (0.182), higher percentage transmittance (95%) and in vitro drug release (97%), an optimum system was designated. Liquid SNEDDS was transformed into free-flowing powder by solid adsorption technique followed by compression into tablets. In vitro release of sertraline from liquid and solid SNEDDS was found to be highly significant compared to plain sertraline (p
publishDate 2018
dc.date.none.fl_str_mv 2018-06-07
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/bjps/article/view/146836
10.1590/s2175-97902018000117232
url https://www.revistas.usp.br/bjps/article/view/146836
identifier_str_mv 10.1590/s2175-97902018000117232
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/bjps/article/view/146836/140365
dc.rights.driver.fl_str_mv Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
dc.source.none.fl_str_mv Brazilian Journal of Pharmaceutical Sciences; Vol. 54 Núm. 1 (2018); e17232
Brazilian Journal of Pharmaceutical Sciences; v. 54 n. 1 (2018); e17232
Brazilian Journal of Pharmaceutical Sciences; Vol. 54 No. 1 (2018); e17232
2175-9790
1984-8250
reponame:Brazilian Journal of Pharmaceutical Sciences
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Brazilian Journal of Pharmaceutical Sciences
collection Brazilian Journal of Pharmaceutical Sciences
repository.name.fl_str_mv Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)
repository.mail.fl_str_mv bjps@usp.br||elizabeth.igne@gmail.com
_version_ 1800222913382580224